S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Did You Get Your Free Bitcoin Yet? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Did You Get Your Free Bitcoin Yet? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Did You Get Your Free Bitcoin Yet? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
Did You Get Your Free Bitcoin Yet? (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:UMRX

Cogent Biosciences (UMRX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free UMRX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$6.44
▼
$6.67
50-Day Range
$2.35
▼
$13.01
52-Week Range
$0.29
▼
$3.72
Volume
1.05 million shs
Average Volume
1.22 million shs
Market Capitalization
$280.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsHeadlinesSocial Media
UMRX stock logo

About Cogent Biosciences Stock (NASDAQ:UMRX)

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

UMRX Stock News Headlines

February 26, 2024 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)
February 26, 2024 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)
April 18, 2024 | InvestorPlace (Ad)
The Next Nvidia?
The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.
February 26, 2024 | markets.businessinsider.com
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential
February 14, 2024 | marketwatch.com
Cogent Biosciences Stock Soars After $225M Private Placement
February 14, 2024 | msn.com
Cogent Biosciences announces oversubscribed $225M private placement
February 9, 2024 | markets.businessinsider.com
Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects
April 18, 2024 | InvestorPlace (Ad)
The Next Nvidia?
The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.
February 8, 2024 | msn.com
Citi starts Cogent Biosciences at buy, cites GI tumor drug potential
December 15, 2023 | markets.businessinsider.com
Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial
December 13, 2023 | markets.businessinsider.com
Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib
December 11, 2023 | markets.businessinsider.com
Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment
December 11, 2023 | markets.businessinsider.com
Dow Surges 100 Points; Cogent Biosciences Shares Plunge
December 11, 2023 | markets.businessinsider.com
Cogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosis
December 11, 2023 | msn.com
Cogent slumps after mid-stage data for rare disorder therapy
November 21, 2023 | markets.businessinsider.com
Potential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Shares
November 14, 2023 | markets.businessinsider.com
Promising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciences
November 4, 2023 | markets.businessinsider.com
Promising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciences
October 28, 2023 | markets.businessinsider.com
Promising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Rating
August 30, 2023 | benzinga.com
Analyst Expectations for Cogent Biosciences's Future
August 15, 2023 | msn.com
Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor
August 8, 2023 | markets.businessinsider.com
LifeSci Capital Remains a Buy on Cogent Biosciences (COGT)
July 11, 2023 | msn.com
Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?
June 13, 2023 | marketwatch.com
Cogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisition
June 12, 2023 | markets.businessinsider.com
9 Analysts Have This to Say About Cogent Biosciences
June 5, 2023 | markets.businessinsider.com
Cogent Biosciences (COGT) Receives a Buy from LifeSci Capital
See More Headlines
Receive UMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2020
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UMRX
CUSIP
N/A
CIK
1622229
Web
www.unumrx.com
Phone
(617) 945-5576
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.04)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,830,000.00
Net Margins
-96.84%
Pretax Margin
N/A
Return on Equity
-87.78%
Return on Assets
-52.14%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
2.90
Quick Ratio
2.90

Sales & Book Value

Annual Sales
$22.50 million
Price / Sales
12.33
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.04 per share
Price / Book
6.28

Miscellaneous

Outstanding Shares
42,469,000
Free Float
N/A
Market Cap
$277.32 million
Optionable
Not Optionable
Beta
3.93
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Andrew R. Robbins
    President, Chief Executive Officer & Director
  • Geoffrey Hodge
    Chief Technical Officer & Senior VP-Operations
  • John L. Green
    Chief Financial & Accounting Officer
  • Jessica Sachs
    Chief Medical Officer
  • Greg Motz
    Head-Research

Key Competitors

View All Competitors

UMRX Stock Analysis - Frequently Asked Questions

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:UMRX) issued its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.03. The firm had revenue of $0.53 million for the quarter. Cogent Biosciences had a negative trailing twelve-month return on equity of 87.78% and a negative net margin of 96.84%.

What other stocks do shareholders of Cogent Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Novan (NOVN), Aeterna Zentaris (AEZS) and Zosano Pharma (ZSAN).

When did Cogent Biosciences IPO?

Cogent Biosciences (UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

This page (NASDAQ:UMRX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
The “Perfect Storm” for Gold
Gold Safe Exchange
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Your Money is Not Safe
American Alternative
The Next Nvidia?
InvestorPlace